Correlation Between Bristol Myers and Hookipa Pharma

Can any of the company-specific risk be diversified away by investing in both Bristol Myers and Hookipa Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and Hookipa Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bristol Myers Squibb and Hookipa Pharma, you can compare the effects of market volatilities on Bristol Myers and Hookipa Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of Hookipa Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and Hookipa Pharma.

Diversification Opportunities for Bristol Myers and Hookipa Pharma

-0.9

Correlation Coefficient

Bristol Myers  Hookipa Pharma

Pay attention - limited upside

The 3 months correlation between Bristol and Hookipa is -0.9. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and Hookipa Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Hookipa Pharma and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with Hookipa Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Hookipa Pharma has no effect on the direction of Bristol Myers i.e., Bristol Myers and Hookipa Pharma go up and down completely randomly.

Pair Corralation between Bristol Myers and Hookipa Pharma

Considering the 90-day investment horizon Bristol Myers Squibb is expected to generate 0.51 times more return on investment than Hookipa Pharma. However, Bristol Myers Squibb is 1.95 times less risky than Hookipa Pharma. It trades about 0.14 of its potential returns per unit of risk. Hookipa Pharma is currently generating about -0.26 per unit of risk. If you would invest  4,996  in Bristol Myers Squibb on September 2, 2024 and sell it today you would earn a total of  926.00  from holding Bristol Myers Squibb or generate 18.53% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Bristol Myers Squibb  vs.  Hookipa Pharma

Bristol Myers Squibb

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal primary indicators, Bristol Myers showed solid returns over the last few months and may actually be approaching a breakup point.

Hookipa Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Hookipa Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with Bristol Myers and Hookipa Pharma

The main advantage of trading using opposite Bristol Myers and Hookipa Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, Hookipa Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hookipa Pharma will offset losses from the drop in Hookipa Pharma's long position.

The idea behind Bristol Myers Squibb and Hookipa Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.